Brief: Amniotics Q2 Loss For Period Narrows To SEK 6.5 Mln
Aug 31 (Reuters) - Amniotics AB (publ) AMNI.ST :
* Q2 RESULT FOR PERIOD: SEK -6.5 (-10.7) MILLION
* STRATEGY IS TO ESTABLISH STRATEGIC PARTNERSHIPS TO HELP
BEAR
DEVELOPMENT COSTS, ESPECIALLY IN LATER STAGES OF CLINICAL
DEVELOPMENT, AND THIS WORK CONTINUES
Source text for Eikon: ID:
Further company coverage: AMNI.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Amniotics AB (publ)
See all newsBrief: Swedish Companies Registration Office Authorises Magle Group, Amniotics Merger Plan
Brief: Amniotics H1 Net Revenue SEK 2.5 Million
Brief: Amniotics Gets Conditional Approval To Delist From Nasdaq First North Growth Market
Brief: Amniotics To Delist From Nasdaq First North Growth Market Upon Magle Group Merger Completion
Brief: Magle Chemoswed, Amniotics Adopt Merger Plan